| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.35 | 1e-10 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.39 | 5e-09 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-08 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.35 | 5e-08 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.24 | 8e-08 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.31 | 9e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.23 | 5e-07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.23 | 7e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 3e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 6e-06 |